Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Wuhan Humanwell Innovative Drug Research And Development Center Limited Company has 2 pending office actions in Biotechnology & Pharmaceuticals. The matters are assigned to 2 distinct examiners and 2 distinct art units. OH, TAYLOR V is the busiest examiner, with 1 pending action.
The pending work is divided across separate technical and examiner assignments. A coordinated portfolio review can identify consistent terminology and disclosure positions, while each response should address the specific art-unit record. The OH matter is one active path among the two, so the data does not support treating that examiner as a dominant concentration point.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| OH, TAYLOR V | 1 | 81.3% | +15.3% |
| HASTINGS, ALISON AZAR | 1 | 62.5% | +42.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18850218 | P2X3 INHIBITOR COMPOUND, SALT THEREOF, POLYMORPH THEREOF AND USE THEREOF | OH, TAYLOR V | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18850218 | P2X3 INHIBITOR COMPOUND, SALT THEREOF, POLYMORPH THEREOF AND USE THEREOF | OH, TAYLOR V | — |
| 18728577 | DIARYL COMPOUND AS TUBULIN/SRC DUAL TARGET INHIBITOR | HASTINGS, ALISON AZAR | — |
| Art Unit | Apps |
|---|---|
| 1625 | 1 |
| 1627 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18850218 | P2X3 INHIBITOR COMPOUND, SALT THEREOF, POLYMORPH THEREOF AND USE THEREOF | OH, TAYLOR V | 1625 | §103§112 | Non-Final OA | — | Pending | Sep 24, 2024 |
| 18728577 | DIARYL COMPOUND AS TUBULIN/SRC DUAL TARGET INHIBITOR | HASTINGS, ALISON AZAR | 1627 | §102§103§112DP | Non-Final OA | — | Pending | Jul 12, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialWuhan Humanwell Innovative Drug Research And Development Center Limited Company has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Taylor V Oh has the most, with 1 of Wuhan Humanwell Innovative Drug Research And Development Center Limited Company's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
